First Supply of CroFab™ Snakebite Antivenom Shipping This Week
Fougera will give priority to filling back orders from 2002

Melville, NY – March 10, 2003 – Fougera^® announced today that the Food and Drug Administration has authorized the first 2003 shipment of their antivenom CroFab^TM; (Crotalidae Polyvalent Immune Fab -- Ovine). Fougera plans to use this shipment to fulfill back orders of CroFab accrued during last year’s antivenom shortage. The average wholesale price of CroFab^TM; is unchanged from January 2002.

“This is a great relief for hospitals that don’t have product on hand,” said Dr. Sean Bush, Staff Emergency Physician & Envenomation Specialist, Loma Linda Medical University Center. “Last year the snakebite season started early and stayed busy. Fortunately, this year hospitals can begin the snakebite season with antivenom stocked.”

CroFab^TM; is indicated for the management of patients with minimal or moderate North American crotalid envenomation. The term crotalid is used to describe the Crotalinae subfamily (formerly known as the Crotalidae family) of venomous snakes that includes rattlesnakes, copperheads and cottonmouths/water moccasins. In October 2002, Fougera assumed responsibility for the distribution of CroFab^TM; from Savage Laboratories. Both companies are divisions of Altana Inc. CroFab^TM; was developed and is manufactured by Protherics PLC. The shelf life of CroFab^TM is 30 months. Complete prescribing information is available at www.fougera.com.

About Fougera
Fougera is a leading manufacturer and distributor of a wide range of multi-source topical and ophthalmic pharmaceuticals in prescription and over-the-counter dosage forms, as well as treatments for emergency/critical care.

CONTACT: Russell LaMontagne of Corinth Group Communications, for Savage Laboratories(R), 212/255-5340